Literature DB >> 1828328

Immune response and Trypanosoma cruzi infection in Trypanosoma rangeli-immunized mice.

B Basso1, E R Moretti, E Vottero-Cima.   

Abstract

The capacity of Trypanosoma rangeli antigens to induce immune response in mice was analyzed and the course of the infection was studied in immunized animals challenged with virulent forms of T. cruzi. BALB/c mice were immunized with supernatant of disrupted epimastigotes of T. rangeli and with epimastigotes (EPI) of T. rangeli fixed with glutaraldehyde. Both of the antigens were emulsified with incomplete Freund's adjuvant (IFrAdj). All of the animals received T. cruzi Tulahuen antigens in the footpad and the skin reactivity was later studied. The mice that received EPI with or without IFrAdj showed significantly higher skin reactivity than controls, both in Arthus (3 hr) and delayed type hypersensitivity (24 hr) reactions. Furthermore, the mice immunized with T. rangeli developed antibodies against T. cruzi detectable through hemagglutination and immunofluorescence tests. When the animals were challenged with trypomastigotes of T. cruzi, only the groups immunized with EPI-IFrAdj had significantly lower parasitemias and greater survival against infection than controls. These results suggest that T. rangeli can induce humoral and cellular immune response against T. cruzi and attenuate the acute period of the infection produced by this parasite. This is the first time that partial resistance to T. cruzi in T. rangeli-immunized mice is reported. These findings may provide a useful tool for future studies directed at the immunoprevention of Chagas' disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1828328     DOI: 10.4269/ajtmh.1991.44.413

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  5 in total

Review 1.  Modulation of immune response in experimental Chagas disease.

Authors:  Beatriz Basso
Journal:  World J Exp Med       Date:  2013-02-20

2.  Immune protection against Trypanosoma cruzi induced by TcVac4 in a canine model.

Authors:  José E Aparicio-Burgos; José A Zepeda-Escobar; Roberto Montes de Oca-Jimenez; José G Estrada-Franco; Alberto Barbabosa-Pliego; Laucel Ochoa-García; Ricardo Alejandre-Aguilar; Nancy Rivas; Giovanna Peñuelas-Rivas; Margarita Val-Arreola; Shivali Gupta; Felix Salazar-García; Nisha J Garg; Juan C Vázquez-Chagoyán
Journal:  PLoS Negl Trop Dis       Date:  2015-04-08

3.  Different serological cross-reactivity of Trypanosoma rangeli forms in Trypanosoma cruzi-infected patients sera.

Authors:  Milene H de Moraes; Alessandra A Guarneri; Fabiana P Girardi; Juliana B Rodrigues; Iriane Eger; Kevin M Tyler; Mário Steindel; Edmundo C Grisard
Journal:  Parasit Vectors       Date:  2008-07-08       Impact factor: 3.876

4.  Vaccination of dogs with Trypanosoma rangeli induces antibodies against Trypanosoma cruzi in a rural area of Córdoba, Argentina.

Authors:  Beatriz Basso; Vanina Marini; Diego Gauna; Maria Frias
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-04       Impact factor: 2.743

5.  Vaccination with Trypanosoma rangeli reduces the infectiousness of dogs experimentally infected with Trypanosoma cruzi.

Authors:  Beatriz Basso; Irma Castro; Virginia Introini; Patricia Gil; Carine Truyens; Edgardo Moretti
Journal:  Vaccine       Date:  2007-03-08       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.